共 265 条
[1]
Fitzmaurice C(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study JAMA Oncol. 3 524-548
[2]
Allen C(2012)EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol. 56 908-943
[3]
Barber RM(2004)BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099-7109
[4]
Barregard L(2007)Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models Cancer Chemother Pharmacol 59 561-574
[5]
Bhutta ZA(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[6]
Wilhelm SM(2009)Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol. 10 25-34
[7]
Carter C(2016)Advances in local and systemic therapies for hepatocellular cancer Curr Oncol Rep. 18 9-6140
[8]
Tang L(2002)Increased exposure of anionic phospholipids on the surface of tumor blood vessels Cancer Res 62 6132-242
[9]
Wilkie D(2003)Regulation of transbilayer plasma membrane phospholipid asymmetry J Lipid Res 44 233-1385
[10]
McNabola A(2008)Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine Clin Cancer Res 14 1377-4416